Sugammadex Injection, Solution
Product Images NDC 70710-1651
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sugammadex (NDC 70710-1651). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (75ac6da6 477a 483f Aced F266e2e8c2a9 02)
Image (75ac6da6 477a 483f Aced F266e2e8c2a9 03)
Image (75ac6da6 477a 483f Aced F266e2e8c2a9 04)
This is a comparison of Cumulative Recovery Rate using Sugammadex and Neostigmine based on time to recovery in minutes. Sugammadex has a faster recovery time of 2.1 minutes compared to Neostigmine's 200 minutes. The graph shows the distribution of recovery times for the two medications. The study includes a group of 38 patients with Vecuronium plus Sugammadex and 35 patients with Vecuronium plus Neostigmine. Medians and quartiles (Q1, Q3) are provided based on product-fit estimates.*
2ml Vial (75ac6da6 477a 483f Aced F266e2e8c2a9 05)
5ml Vial (75ac6da6 477a 483f Aced F266e2e8c2a9 06)
This text provides important information about a medication called Sugammadex, which is intended for intravenous use only. It is available in a 500 mg/5 mL strength and is stored at 25°C. The medication should be protected from light and is supplied in a 5mL single-dose vial. The dosage details and storage instructions are provided for healthcare professionals. It is distributed by Zydus Pharmaceuticals (USA) Inc.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.